Latest Manufacturing Processes News

Weebit Nano Ltd (ASX: WBT) has opened a non-underwritten Share Purchase Plan (SPP) offering eligible shareholders in Australia and New Zealand the chance to buy up to A$30,000 worth of shares at A$4.05 each. The company aims to raise up to A$15 million to support the commercialisation of its Resistive RAM (ReRAM) technology.

BluGlass Limited (ASX: BLG) has entered a A$1.3 million strategic collaboration with a Fortune 500 global data storage company to advance photonics research using its proprietary visible laser technology.

Perpetual Resources has secured a significant tungsten exploration package in Brazil’s Seridó Mineral Province, aiming to capitalise on rising demand for this critical mineral amid global supply constraints.

AdAlta’s subsidiary AdCella has completed its first Joint Development Committee meeting with Shanghai Cell Therapy Group, advancing the development of the CAR-T therapy BZDS1901 with potential timeline acceleration and reduced regulatory risks.

Osteopore Limited has drawn down an additional $250,000 on the second tranche of its redeemable convertible notes, continuing its strategic funding partnership with Advance Opportunities Fund. This incremental funding supports the company’s ongoing business and future growth initiatives.

AML3D has landed a nearly $10 million order for four ARCEMY X 6700 systems from Newport News Shipbuilding, expanding its footprint in the US defence manufacturing sector.

1414 Degrees Ltd posted a steep 192% rise in half-year losses to $3.86 million, while advancing its silicon-based energy storage and hydrogen technologies. The company also faces uncertainty after its joint venture partner Vast Renewables entered administration.

Metal Powder Works Limited reported a substantial increase in its half-year loss to $3.7 million, driven by investments in production scaling and market expansion. Revenue more than doubled, reflecting strong demand in defence, aerospace, and nuclear sectors.

NeuroScientific Biopharmaceuticals reported a $1.7 million loss for the half-year ending December 2025, driven by ongoing R&D investments. The company progressed clinical treatments for Crohn’s disease and glaucoma, alongside key leadership appointments and strategic partnerships.

Argent BioPharma has completed its largest commercial shipment of CannEpil® to Ireland, marking a key milestone in its European expansion with a delivery valued at approximately AUD 783,000. The product is fully reimbursed under Ireland’s National Health Insurance scheme, enhancing patient access for refractory epilepsy treatment.

AdAlta Limited reported a $2.44 million loss for H1 FY26 while progressing a key CAR-T therapy collaboration and raising $2.8 million in capital. The company’s ‘East to West’ immunotherapy strategy gains momentum with regulatory tailwinds and cost efficiencies.

Arovella Therapeutics reported a 22% increase in half-year losses to $1.88 million while securing FDA acceptance of its IND application for lead asset ALA-101, paving the way for first-in-human trials.